Cinctive Capital Management LP Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cinctive Capital Management LP bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 128,147 shares of the specialty pharmaceutical company’s stock, valued at approximately $14,277,000. Cinctive Capital Management LP owned 0.21% of Jazz Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in JAZZ. EverSource Wealth Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC increased its stake in Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the period. Arizona State Retirement System lifted its position in Jazz Pharmaceuticals by 0.8% in the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after purchasing an additional 130 shares during the last quarter. Cardinal Capital Management lifted its position in Jazz Pharmaceuticals by 1.9% in the second quarter. Cardinal Capital Management now owns 12,068 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after purchasing an additional 227 shares during the last quarter. Finally, Waterfront Wealth Inc. boosted its stake in shares of Jazz Pharmaceuticals by 2.5% during the second quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company’s stock valued at $1,004,000 after purchasing an additional 230 shares during the period. Institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on JAZZ shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Piper Sandler reissued an “overweight” rating and issued a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Finally, JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.33.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock valued at $720,160 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $121.59 on Monday. The company’s fifty day moving average price is $114.87 and its 200-day moving average price is $111.13. The stock has a market cap of $7.35 billion, a PE ratio of 17.13, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.